Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA)

As you know, Akebia Therapeutics, Inc. ( AKBA ) makes money mainly via the commercialisation of Vafseo. It's an oral therapy approved for the treatment of anaemia due to chronic kidney disease (CKD) in adults receivingI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation f ...